Suppr超能文献

急性复发性和慢性胰腺炎作为囊性纤维化和囊性纤维化跨膜电导调节因子相关疾病的初始表现。

Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders.

机构信息

Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of California, San Francisco, San Francisco, CA.

出版信息

Pancreas. 2019 Aug;48(7):888-893. doi: 10.1097/MPA.0000000000001350.

Abstract

OBJECTIVES

Recurrent pancreatitis is considered a rare manifestation of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction; this case series highlights that pancreatitis can be a presenting symptoms of cystic fibrosis (CF) or a CFTR-related disorder (CFTR-RD).

METHODS

Retrospective review of patients younger than 30 years diagnosed as having acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) and subsequently diagnosed as having CF or CFTR-RD.

RESULTS

Among 18 patients, median time from diagnosis of ARP/CP to diagnosis of CF was 0.4 years (range, 0-33 years). Eight were classified as having CF by elevated sweat chloride testing (SCT). Five had intermediate SCT (30-59 mmol/L) with 2 pathogenic mutations. Five had CFTR-RD with intermediate SCT and 0 to 1 pathogenic mutations. Eight patients (44%) had exocrine pancreatic insufficiency, and pancreatic fluid collections were more common in this group. Based on the CFTR mutation, 6 patients were eligible for CFTR potentiator therapy, although none received it during the study period. Nine of the 18 had ≥1 other likely CF manifestations, including sinusitis (33%), nasal polyps (11%), pneumonia (22%), and gallbladder disease (22%).

CONCLUSIONS

Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.

摘要

目的

复发性胰腺炎被认为是囊性纤维化跨膜电导调节因子(CFTR)功能障碍的罕见表现;本病例系列强调,胰腺炎可能是囊性纤维化(CF)或 CFTR 相关疾病(CFTR-RD)的首发症状。

方法

回顾性分析了年龄小于 30 岁的急性复发性胰腺炎(ARP)或慢性胰腺炎(CP)患者,这些患者随后被诊断为 CF 或 CFTR-RD。

结果

在 18 名患者中,从 ARP/CP 诊断到 CF 诊断的中位时间为 0.4 年(范围,0-33 年)。8 例通过升高的汗液氯测试(SCT)被归类为 CF。5 例 SCT 为中间值(30-59mmol/L),有 2 个致病性突变。5 例 CFTR-RD 伴有中间 SCT 和 0 至 1 个致病性突变。8 例(44%)有外分泌胰腺功能不全,该组胰腺液体积聚更为常见。根据 CFTR 突变,有 6 名患者有资格接受 CFTR 增强剂治疗,尽管在研究期间没有接受治疗。18 名患者中有 9 名(44%)有≥1 种其他可能的 CF 表现,包括鼻窦炎(33%)、鼻息肉(11%)、肺炎(22%)和胆囊疾病(22%)。

结论

CF 或 CFTR-RD 可表现为 ARP/CP。对 ARP/CP 患者进行 CFTR-RD 的全面诊断性检测将扩大治疗选择,并有助于识别合并症。

相似文献

2
Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders.
Arch Pediatr. 2020 Feb;27 Suppl 1:eS25-eS29. doi: 10.1016/S0929-693X(20)30047-6.
3
[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):352-372. doi: 10.3760/cma.j.cn112147-20221214-00971.
4
Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
Pediatrics. 2005 Apr;115(4):e463-9. doi: 10.1542/peds.2004-1764. Epub 2005 Mar 16.
6
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.
J Cyst Fibros. 2012 Sep;11(5):355-62. doi: 10.1016/j.jcf.2012.05.001. Epub 2012 Jun 2.
8
The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis.
Hum Genet. 2005 Dec;118(3-4):372-81. doi: 10.1007/s00439-005-0059-z. Epub 2005 Sep 29.
9
The diagnosis of cystic fibrosis.
Presse Med. 2017 Jun;46(6 Pt 2):e97-e108. doi: 10.1016/j.lpm.2017.04.010. Epub 2017 May 31.
10
Cystic fibrosis transmembrane conductance regulator ion channel function testing in recurrent acute pancreatitis.
J Clin Gastroenterol. 2008 Aug;42(7):810-4. doi: 10.1097/MCG.0b013e318156617c.

引用本文的文献

3
Accurate and Automated Genotyping of the Poly-T/TG Tract with -TIPS.
Int J Mol Sci. 2024 Aug 5;25(15):8533. doi: 10.3390/ijms25158533.
4
Diagnosing Cystic Fibrosis in the 21st Century-A Complex and Challenging Task.
Diagnostics (Basel). 2024 Apr 3;14(7):763. doi: 10.3390/diagnostics14070763.
6
CFTR:F508d/A613T Mutation Is Associated With Recurrent Episodes of Pancreatitis.
JPGN Rep. 2021 Nov 29;3(1):e142. doi: 10.1097/PG9.0000000000000142. eCollection 2022 Feb.
7
No Stone Left Unturned: Pediatric Pancreatic Stones Presenting With Obstructive Jaundice.
JPGN Rep. 2022 Jun 21;3(3):e217. doi: 10.1097/PG9.0000000000000217. eCollection 2022 Aug.
9
Surgical considerations in cystic fibrosis: what every general surgeon needs to know.
ANZ J Surg. 2022 Oct;92(10):2425-2432. doi: 10.1111/ans.17948. Epub 2022 Aug 3.
10
Pancreatic complications in children with cystic fibrosis.
Curr Opin Pediatr. 2020 Oct;32(5):661-667. doi: 10.1097/MOP.0000000000000934.

本文引用的文献

1
Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis.
Am J Gastroenterol. 2018 Jul;113(7):1058-1059. doi: 10.1038/s41395-018-0123-7. Epub 2018 Jun 11.
2
Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor: Case Series.
J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):451-454. doi: 10.1097/MPG.0000000000001788.
3
Pancreatitis and pancreatic cystosis in Cystic Fibrosis.
J Cyst Fibros. 2017 Nov;16 Suppl 2:S79-S86. doi: 10.1016/j.jcf.2017.07.004.
5
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.
J Pediatr. 2017 Feb;181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064.
6
Risk Factors Associated With Pediatric Acute Recurrent and Chronic Pancreatitis: Lessons From INSPPIRE.
JAMA Pediatr. 2016 Jun 1;170(6):562-9. doi: 10.1001/jamapediatrics.2015.4955.
7
CFTR: A New Horizon in the Pathomechanism and Treatment of Pancreatitis.
Rev Physiol Biochem Pharmacol. 2016;170:37-66. doi: 10.1007/112_2015_5002.
10
Pulmonary disease in cystic fibrosis: assessment with chest CT at chest radiography dose levels.
Radiology. 2014 Nov;273(2):597-605. doi: 10.1148/radiol.14132201. Epub 2014 Jul 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验